Figure 4

Probabilistic sensitivity analysis of the incremental costs and effectiveness (QALYs) for RI-HSCT vs BT-ICT presented on a cost-effectiveness plane. RI-HSCT: Reduced intensity hematopoietic stem cell transplantation; BT-ICT: Blood transfusion combined with iron chelating therapy; QALYs: quality adjusted life-years.